13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00674141
(ClinicalTrials.gov)
July 20086/5/2008Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) TreatmentNasal Administration of Dexamethasone for MS TreatmentMS Patient With Relpasing Remitting AttacksDrug: Dexamethasone soduim phosphateHadassah Medical OrganizationNULLWithdrawn18 YearsN/ABoth10Phase 1Israel
2EUCTR2006-003113-40-NL
(EUCTR)
18/08/200621/07/2006Dexamethason for the treatment of exacerbations in multiple sclerosisDexamethason for the treatment of exacerbations in multiple sclerosis Multiple Sclerosis
MedDRA version: 8.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis
Product Name: Dexamethason
INN or Proposed INN: Dexamethasone
Department of Neurology UMCGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Netherlands